| Biological Information | |
|---|---|
| Background Information: | N-Terminal 6His-tagged, recombinant, human CDKL5, amino acids 1-402. CDKL5 regulates axon outgrowth, dendritic morphogenesis and synapse formation in early postnatal life. It also plays a role in maintaining synaptic function in the adult brain and may regulate ciliogenesis. Pathologic mutations in cyclin-dependent kinase-like 5 cause CDKL5 deficiency disorder (CDD), a developmental and epileptic encephalopathy (DEE) with infantile-onset epilepsy, global developmental delay with subsequent intellectual and motor disabilities, and cortical visual impairment. |
| Target Class: | Kinase |
| Family: | CMGC (CDK, MAPK, GSK, CLK, DYRK, SRPK) |
| Sub Family: | Serine/threonine kinase |
| Accession Number: | NM_003159.3 |
| Target Name: | CDKL5 |
| Target Aliases: | CDKL5, STK9, ISSX, Cyclin-dependent kinase-like 5 Serine/threonine-protein kinase 19, O76039 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 12 months at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent applications and subject to a Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
| Assay Information | |
| Assay Type: | Biochemical |
| Clinical Relevance | |
| Therapeutic Area: | Developmental disorders |
CDKL5, active
10 µg of active CDKL5. N-Terminal 6His-tagged, recombinant, human CDKL5, amino acids 1-402.
Datasheets
14-998_Datasheet
View Document